SAILIFE

Sai Life Science Share Price

 

 

Invest in Sai Life Science with 3.24X leverage

Invest with MTF

Performance

  • Low
  • ₹816
  • High
  • ₹846
  • 52 Week Low
  • ₹636
  • 52 Week High
  • ₹983
  • Open Price₹816
  • Previous Close₹808
  • Volume651,204
  • 50 DMA₹888.86
  • 100 DMA₹875.14
  • 200 DMA₹828.73

Investment Returns

  • Over 1 Month -9.98%
  • Over 3 Month -6.24%
  • Over 6 Month + 2.44%
  • Over 1 Year + 15.91%

Smart Investing Starts Here Start SIP with Sai Life Science for Steady Growth!

Invest Now

Sai Life Science Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 60.9
  • PEG Ratio
  • 0.5
  • Market Cap Cr
  • 17,449
  • P/B Ratio
  • 7.7
  • Average True Range
  • 29.68
  • EPS
  • 13.56
  • Dividend Yield
  • 0
  • MACD Signal
  • -2.92
  • RSI
  • 35.94
  • MFI
  • 58.03

Sai Life Science Financials

Sai Life Science Technicals

EMA & SMA

Current Price
₹826.05
+ 17.75 (2.2%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹883.10
  • 50 Day
  • ₹888.86
  • 100 Day
  • ₹875.14
  • 200 Day
  • ₹828.73

Resistance and Support

829.13 Pivot Speed
  • R3 873.12
  • R2 859.48
  • R1 842.77
  • S1 812.42
  • S2 798.78
  • S3 782.07

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Sai Life Sciences, a leading CRDMO, partners with 280+ global pharma and biotech companies to accelerate NCE small molecule programs. across India, UK, USA, and Japan, it ensures quality and compliance through USFDA-certified facilities.

Sai Life Sciences Ltd has an operating revenue of Rs. 2,053.17 Cr. on a trailing 12-month basis. An annual revenue growth of 16% is outstanding, Pre-tax margin of 13% is healthy, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and close to its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It has recently broken out of a base in its weekly chart but failed to keep its momentum and is trading around -14% from the pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 99 which is a GREAT score indicating consistency in earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 111 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Sai Life Science Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-06 Quarterly Results
2025-08-07 Quarterly Results
2025-05-13 Audited Results
2025-02-06 Quarterly Results

Sai Life Science F&O

Sai Life Science Shareholding Pattern

34.7%
27.57%
3.24%
21.41%
5.94%
7.14%

About Sai Life Science

  • NSE Symbol
  • SAILIFE
  • BSE Symbol
  • 544306
  • Managing Director & CEO
  • Mr. Krishnam Raju Kanumuri
  • ISIN
  • INE570L01029

Similar Stocks to Sai Life Science

Sai Life Science FAQs

Sai Life Science share price is ₹826 As on 22 January, 2026 | 21:51

The Market Cap of Sai Life Science is ₹17448.8 Cr As on 22 January, 2026 | 21:51

The P/E ratio of Sai Life Science is 60.9 As on 22 January, 2026 | 21:51

The PB ratio of Sai Life Science is 7.7 As on 22 January, 2026 | 21:51

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23